Search Results - "Lok, A S"

All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database by Reddy, K. R., Lim, J. K., Kuo, A., Di Bisceglie, A. M., Galati, J. S., Morelli, G., Everson, G. T., Kwo, P. Y., Brown, R. S., Sulkowski, M. S., Akuschevich, L., Lok, A. S., Pockros, P. J., Vainorius, M., Terrault, N. A., Nelson, D. R., Fried, M. W., Manns, M. P.

“…Summary Background Chronic hepatitis C virus therapy in patients with advanced liver disease remains a clinical challenge. HCV‐TARGET collects data in patients…”
Get full text

Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study by Ahn, J., Lee, H. M., Lim, J. K., Pan, C. Q., Nguyen, M. H., Ray Kim, W., Mannalithara, A., Trinh, H., Chu, D., Tran, T., Min, A., Do, S., Te, H., Reddy, K. R., Lok, A. S.

“…Summary Background Entecavir (ETV) has been shown to be safe and efficacious in randomised controlled trials in highly selected patients with hepatitis B virus…”
Get full text

Recipient Morbidity After Living and Deceased Donor Liver Transplantation: Findings from the A2ALL Retrospective Cohort Study by Freise, C. E., Gillespie, B. W., Koffron, A. J., Lok, A. S. F., Pruett, T. L., Emond, J. C., Fair, J. H., Fisher, R. A., Olthoff, K. M., Trotter, J. F., Ghobrial, R. M., Everhart, J. E.

“…Patients considering living donor liver transplantation (LDLT) need to know the risk and severity of complications compared to deceased donor liver…”
Get full text

Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort by Kulik, L. M., Fisher, R. A., Rodrigo, D. R., Brown, Jr, R. S., Freise, C. E., Shaked, A., Everhart, J. E., Everson, G. T., Hong, J. C., Hayashi, P. H., Berg, C. L., Lok, A. S. F.

“…Hepatocellular carcinoma (HCC) represents an increasing fraction of liver transplant indications; the role of living donor liver transplant (LDLT) remains…”
Get full text

Hepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver Transplantation by Fisher, R. A., Kulik, L. M., Freise, C. E., Lok, A. S. F., Shearon, T. H., Brown, R. S., Ghobrial, R. M., Fair, J. H., Olthoff, K. M., Kam, I., Berg, C. L.

“…We examined mortality and recurrence of hepatocellular carcinoma (HCC) among 106 transplant candidates with cirrhosis and HCC who had a potential living donor…”
Get full text

IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection by Rao, H.-Y., Sun, D.-G., Jiang, D., Yang, R.-F., Guo, F., Wang, J.-H., Liu, F., Zhang, H.-Y., Zhang, H.-H., Du, S.-C., Jin, Q., Qin, H., Lok, A.-S.-F., Wei, L.

“…Single nucleotide polymorphisms (SNPs) near the IL28B gene have been shown to be associated with response to treatment for chronic hepatitis C and also with…”
Get full text

Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring – predictors and predictive models of disease progression by Konerman, M. A., Yapali, S., Lok, A. S.

“…Summary Background Advances in hepatitis C therapies have led to increasing numbers of patients seeking treatment. As a result, logistical and financial…”
Get full text

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference by Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., Colombo, M., Delarocque-Astagneau, E., Dusheiko, G., Esmat, G., Esteban, R., Goldberg, D., Gore, C., Lok, A. S. F., Manns, M., Marcellin, P., Papatheodoridis, G., Peterle, A., Prati, D., Piorkowsky, N., Rizzetto, M., Roudot-Thoraval, F., Soriano, V., Thomas, H. C., Thursz, M., Valla, D., van Damme, P., Veldhuijzen, I. K., Wedemeyer, H., Wiessing, L., Zanetti, A. R., Janssen, H. L. A.

“…Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600 000 and 350 000 deaths each year. Viral hepatitis is the…”
Get full text

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants by Funk, M. L., Rosenberg, D. M., Lok, A. S. F.

“…Hepatitis B is a serious disease that is endemic in many parts of the world. A significant proportion of patients with chronic hepatitis B (CHB) are infected…”
Get full text

Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data by Konerman, M. A., Brown, M., Zheng, Y., Lok, A. S. F

“…Summary Accuracy of risk assessments for clinical outcomes in patients with chronic liver disease has been limited given the nonlinear nature of disease…”
Get full text

Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation by Degertekin, B., Han, Steven‐Huy B., Keeffe, E. B., Schiff, E. R., Luketic, V. A., Brown, Jr, R. S., Emre, S., Soldevila‐Pico, C., Reddy, K. R., Ishitani, M. B., Tran, T. T., Pruett, T. L., Lok, A. S. F.

“…The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has reduced but not eliminated hepatitis B virus (HBV) recurrence…”
Get full text

Variation in Organ Quality between Liver Transplant Centers by Volk, M. L., Reichert, H. A., Lok, A. S. F., Hayward, R. A.

“…A wide spectrum of quality exists among deceased donor organs available for liver transplantation. It is unknown whether some transplant centers systematically…”
Get full text

Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States by Wai, C.-T., Fontana, R. J., Polson, J., Hussain, M., Shakil, A. O., Han, S.-H., Davern, T. J., Lee, W. M., Lok, A. S.-F

“…The role of hepatitis B virus (HBV) genotypes in the outcome of acute HBV infection is unclear. In this study, we aimed to evaluate the clinical and…”
Get full text

The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre by SINGAL, A. G., RAKOSKI, M. O., SALGIA, R., PELLETIER, S., WELLING, T. H., FONTANA, R. J., LOK, A. S., MARRERO, J. A.

“…Aliment Pharmacol Ther 31, 625–633 Summary Background  The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well…”
Get full text

Occult hepatitis B virus infection: A hidden menace? by Conjeevaram, Hari S., Lok, Anna S.

Get full text

The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease by Rao, H., Wu, E., Fu, S., Yang, M., Feng, B., Lin, A., Fei, R., Fontana, R. J., Lok, A. S., Wei, L.

“…Summary Background Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the United States (US) and…”
Get full text

Management of hepatitis C patients by primary care physicians in the USA: results of a national survey by Shehab, T. M., Sonnad, S. S., Lok, A. S. F.

“…Hepatitis C is a major health problem worldwide, yet very little research has been performed to assess the knowledge base and practice patterns of primary care…”
Get full text

Diagnosis of hepatitis C by Lok, A S, Gunaratnam, N T

“…Currently, the second‐ and third‐generation enzyme immunoassays (EIA‐2 and EIA‐3) for hepatitis C virus antibody (anti‐HCV) are the most practical screening…”
Get full text

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy by Evon, D. M., Amador, J., Stewart, P., Reeve, B. B., Lok, A. S., Sterling, R. K., Di Bisceglie, A. M., Reau, N., Serper, M., Sarkar, S., Lim, J. K., Golin, C. E., Fried, M. W.

“…Summary Background To better understand symptoms experienced by patients infected with chronic hepatitis C virus (HCV), valid and reliable patient‐reported…”
Get full text

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs by Chotiyaputta, W., Hongthanakorn, C., Oberhelman, K., Fontana, R. J., Licari, T., Lok, A. S. F.

“…Medication adherence is important for the success of nucleos(t)ide analogue (NUC) treatment for chronic hepatitis B. The aims of this study were to determine…”
Get full text